#news #biotech Scynexis’ new antifungal heads to phase 3 for yeast infections

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scynexis’ new antifungal heads to phase 3 for yeast infections .A novel antifungal developed by Scynexis for the yeast infection vulvovaginal candidiasis has bested the current standard therapy in a mid-stage trial and is moving to a phase 3 program.

from FierceBiotech: Biotech https://ift.tt/2JcR459